Neurogene Inc. (NGNE) compared with its closest peers (GYRE, ESPR, MNPR, PHAT, CTMX). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Gyre Therapeutics, Esperion Therapeutics, Monopar Therapeutics, Phathom Pharmaceuticals, CytomX Therapeutics, Ironwood Pharmaceuticals, Zevra Therapeutics, Rigel Pharmaceuticals, Cryoport and Collegium Pharmaceutical share Neurogene's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $768.30M | 352.0 |
| Esperion Therapeutics, Inc. (ESPR) | $821.21M | -33.7 |
| Monopar Therapeutics Inc. (MNPR) | $725.08M | -35.4 |
| Phathom Pharmaceuticals, Inc. (PHAT) | $718.00M | -5.5 |
| CytomX Therapeutics, Inc. (CTMX) | $714.71M | -28.5 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Zevra Therapeutics, Inc. (ZVRA) | $701.40M | 6.4 |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Cryoport, Inc. (CYRX) | $866.86M | 6.9 |
| Collegium Pharmaceutical, Inc. (COLL) | $882.75M | 19.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NGNE overview · NGNE earnings · NGNE financials · NGNE KPIs · NGNE documents · NGNE ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.